EP2980218A1 — Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
Assigned to Rheinische Friedrich Wilhelms Universitaet Bonn · Expires 2016-02-03 · 10y expired
What this patent protects
The present invention relates to a complex formed by thrombin and a thrombin-binding aptamer, said complex is capable of neutralizing the activity of a direct acting thrombin inhibitor, and to a use as an antidote to blood anticoagulants selected from direct acting thrombin inhib…
USPTO Abstract
The present invention relates to a complex formed by thrombin and a thrombin-binding aptamer, said complex is capable of neutralizing the activity of a direct acting thrombin inhibitor, and to a use as an antidote to blood anticoagulants selected from direct acting thrombin inhibitors.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.